Event Schedule
  • Communicate the level of validation needed in order to make claims on data
  • Upgrade due diligence around the technologies that clinical trial teams must have in place
  • Bridge gaps in levels of inherent knowledge
  • Explore select differences in launching hybrid decentralized studies in Europe, Asia Pacific and South America
  • Discuss flexible approaches for eConsent, telehealth, eCOA sensors and home health
  • Review lessons learned to date with global DCT expansion
  • Reduce the need for site visits through at-home monitoring
  • Gather and reliably archive patient feedback on drug formulation and delivery
  • Turn a challenging time into new opportunity, with trial structures that more easily fit into patients’ routines
  • Explore the potential of remote models
  • Recognize and adapt to burdens and complexities of multiple stakeholders
  • Evaluate vendor capabilities to move beyond virtual sites and take on both CRO and site capabilities
  • Understand the regulatory guidance available and consider the implications to the regulatory strategy for products that use these novel approaches in clinical trials.
  • Utilize novel approaches to clinical trials within a context of COVID-19
  • Explore the US FDA guidance documents published related to COVID-19 pandemic and provide regulatory insights as to moving forward in our ‘new normal’ of clinical trial development.
  • Leverage a single destination for all trial virtualization technologies
  • Incorporate and harness the patient voice in the design of a decentralized trial
  • Improve patient access to clinical trials using registries
  • Review how the industry combines conventional strategies with virtual trials
  • Restructure internal processes as needed for implementation
  • Investigate the most cost-effective applications and outcomes
  • Analyze how digital health tools can move trials forward
  • Ensure the data integrity and subjects' safety monitoring in the virtual clinical trials implementation
  • Explore areas requiring change in order to drive sustaining adoption in the organization
  • Discuss specific examples spanning processes, vendor selection, training and protocol authoring
  • Share experiences managing organizational change to recognize pitfalls and drivers of success
  • Hear the insights gained from designing and implementing transformational solutions for the new era that will propel the future of drug development
  • Discover how to use a lens of business-to-consumer product evolution
  • Examine actual client needs from this past year as case studies showing how we can shape an “Amazon experience”
  • Identify and increase focus on patients and evolving customer needs to deliver solutions that are relevant and long-lasting
  • Outline how the proper technology choices can help or hinder you
  • Compare and contrast technical platform options
  • Focus on the clinical trial without commercial consideration
  • Evaluate the benefits of virtual meetings in terms of cost and convenience
  • Compare different methods for gathering information through “breakouts
  • Review new outreach options for CRAs and training
  • Clarify in advance the needs for tech support
  • Explore the most up-to-date options for large-scale data analysis for virtual trials
  • Address common mistakes and misperceptions
  • Clarify what is realistically possible for digital health and bioinformatics in a remote setting
  • Determine the most important indicators of site quality
  • Plan creative collaboration and flexible strategies
  • Find the fastest techniques for site quality maximization
  • Recognize how behavior influences team results